Doug Ingram, Sarepta CEO (Sarepta)

FDA knocks back Sarep­ta in Duchenne gene ther­a­py race with Pfiz­er, but an­a­lysts urge cau­tion

Sarep­ta has gone all-in on gene ther­a­py over the last few years, rac­ing with Pfiz­er and Sol­id Bio­sciences to be the first to de­vel­op a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.